Comparative Pharmacology
Head-to-head clinical analysis: KELNOR versus TRI MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KELNOR versus TRI MILI.
KELNOR vs TRI-MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combined oral contraceptive; inhibits ovulation by suppressing gonadotropin release (FSH and LH) primarily via progestational activity; increases viscosity of cervical mucus to inhibit sperm penetration; alters endometrium.
TRI-MILI is a combination of norethindrone (a progestin) and ethinyl estradiol (an estrogen). Norethindrone suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol stabilizes the endometrium and potentiates the progestational effects.
KELNOR (norethindrone acetate and ethinyl estradiol) is a combined oral contraceptive. Typical adult dose: 1 tablet (norethindrone acetate 1 mg/ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 placebo tablets, starting on day 1 of menstrual cycle.
For mild-to-moderate hypertension: 1 tablet (containing triamterene 50 mg and hydrochlorothiazide 25 mg) orally once daily. May increase to 2 tablets daily if needed. Maximum dose: 4 tablets daily.
None Documented
None Documented
Terminal elimination half-life 12-15 hours; clinically relevant for once-daily dosing.
Terminal elimination half-life is 6-9 hours in adults with normal renal function, allowing twice-daily dosing; prolonged in renal impairment.
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (10-15%); biliary/fecal elimination accounts for <5%.
Renal excretion of unchanged drug accounts for 60-80% of elimination; biliary/fecal excretion accounts for 15-25%; remainder metabolized.
Category C
Category C
Oral Contraceptive
Oral Contraceptive